These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

440 related articles for article (PubMed ID: 16826593)

  • 1. Recommendations for the use of yttrium-90 ibritumomab tiuxetan in malignant lymphoma.
    Weigert O; Illidge T; Hiddemann W; Dreyling M
    Cancer; 2006 Aug; 107(4):686-95. PubMed ID: 16826593
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radioimmunotherapy for patients with relapsed B-cell non-Hodgkin lymphoma.
    Witzig TE
    Cancer Chemother Pharmacol; 2001 Aug; 48 Suppl 1():S91-5. PubMed ID: 11587375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radioimmunotherapy for NHL: experience of 90Y-ibritumomab tiuxetan in clinical practice.
    Hagenbeek A
    Leuk Lymphoma; 2003; 44 Suppl 4():S37-47. PubMed ID: 15154741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.
    Wiseman GA; Kornmehl E; Leigh B; Erwin WD; Podoloff DA; Spies S; Sparks RB; Stabin MG; Witzig T; White CA
    J Nucl Med; 2003 Mar; 44(3):465-74. PubMed ID: 12621016
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of 90Y-ibritumomab tiuxetan in non-Hodgkin's lymphoma.
    Marcus R
    Semin Oncol; 2005 Feb; 32(1 Suppl 1):S36-43. PubMed ID: 15786024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma.
    Gordon LI; Witzig T; Molina A; Czuczman M; Emmanouilides C; Joyce R; Vo K; Theuer C; Pohlman B; Bartlett N; Wiseman G; Darif M; White C
    Clin Lymphoma; 2004 Sep; 5(2):98-101. PubMed ID: 15453924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Yttrium-90 ibritumomab tiuxetan-induced complete remission in a patient with classical lymphocyte-rich Hodgkin's Lymphoma.
    Schnell R; Dietlein M; Schomäcker K; Kobe C; Borchmann P; Schicha H; Hallek M; Engert A
    Onkologie; 2008 Feb; 31(1-2):49-51. PubMed ID: 18268399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.
    Witzig TE; Gordon LI; Cabanillas F; Czuczman MS; Emmanouilides C; Joyce R; Pohlman BL; Bartlett NL; Wiseman GA; Padre N; Grillo-López AJ; Multani P; White CA
    J Clin Oncol; 2002 May; 20(10):2453-63. PubMed ID: 12011122
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Full-dose 90Y ibritumomab tiuxetan therapy is safe in patients with prior myeloablative chemotherapy.
    Jacobs SA; Vidnovic N; Joyce J; McCook B; Torok F; Avril N
    Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7146s-7150s. PubMed ID: 16203814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ongoing trials with yttrium 90-labeled ibritumomab tiuxetan in patients with non-Hodgkin's lymphoma.
    Micallef IN
    Clin Lymphoma; 2004 Oct; 5 Suppl 1():S27-32. PubMed ID: 15498147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of radioimmunotherapy with yttrium-90 ibritumomab tiuxetan in the treatment of non-Hodgkin lymphoma.
    Cheson BD
    BioDrugs; 2005; 19(5):309-22. PubMed ID: 16207072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Yttrium-90-ibritumomab tiuxetan radioimmunotherapy: a new treatment approach for B-cell non-Hodgkin's lymphoma.
    Witzig TE
    Drugs Today (Barc); 2004 Feb; 40(2):111-9. PubMed ID: 15045033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma.
    Ansell SM; Ristow KM; Habermann TM; Wiseman GA; Witzig TE
    J Clin Oncol; 2002 Sep; 20(18):3885-90. PubMed ID: 12228209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for patients with relapsed CD20+ B-cell non-Hodgkin's lymphoma.
    Alcindor T; Witzig TE
    Curr Treat Options Oncol; 2002 Aug; 3(4):275-82. PubMed ID: 12074764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nursing a patient during and after 90Y-ibritumomab tiuxetan (Zevalin) therapy.
    Clayton J
    Leuk Lymphoma; 2003; 44 Suppl 4():S49-55. PubMed ID: 15154742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Yttrium 90 ibritumomab tiuxetan in lymphoma.
    Cheung MC; Haynes AE; Stevens A; Meyer RM; Imrie K;
    Leuk Lymphoma; 2006 Jun; 47(6):967-77. PubMed ID: 16840185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of 90Y ibritumomab tiuxetan (Zevalin) radioimmunotherapy for non-Hodgkin's lymphoma.
    Witzig TE
    Semin Oncol; 2003 Dec; 30(6 Suppl 17):11-6. PubMed ID: 14710398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ibritumomab tiuxetan for non-Hodgkin's lymphoma.
    Johnston PB; Bondly C; Micallef IN
    Expert Rev Anticancer Ther; 2006 Jun; 6(6):861-9. PubMed ID: 16761929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Report of a European consensus workshop to develop recommendations for the optimal use of (90)Y-ibritumomab tiuxetan (Zevalin) in lymphoma.
    Hagenbeek A; Lewington V
    Ann Oncol; 2005 May; 16(5):786-92. PubMed ID: 15802280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin).
    Riley MB; Gordon LI
    Semin Oncol Nurs; 2004 Feb; 20(1 Suppl 1):8-13. PubMed ID: 15160856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.